Peer

Efficacy of 4% articaine vs 2% lidocaine in mandibular and maxillary block and infiltration anaesthesia in patients with irreversible pulpitis: a systematic review and meta-analysis

Sanjay Miglani¹, Irfan Ansari¹, Swadheena Patro², Ankita Mohanty², Shahnaz Mansoori³, Bhoomika Ahuja⁴, Mohmed Isaqali Karobari^{5,6}, Krishna Prasad Shetty^{7,8}, Musab Hamed Saeed^{7,8}, Alexander Maniangat Luke^{7,8} and Ajinkya M. Pawar⁹

¹ Department of Conservative Dentistry & Endodontics, Faculty of Dentistry, Jamia Millia Islamia (A Central University), Okhla, New Delhi, India, Delhi, India

² Department of Conservative Dentistry & Endodontics, Kalinga Institute of Dental Sciences, Bhubaneswar, Odisha, India, Bhubaneswar, India

³ Department of Public Health, Faculty of Dentistry, Jamia Millia Islamia (A Central University), Okhla, New Delhi, India, Delhi, India

⁴ Department of Paediatric Dentistry, K D Dental College, Mathura, Uttar Pardesh, India, Mathura, India

⁵ Conservative Dentistry Unit, School of Dental Sciences, Universiti Sains Malaysia, Health Campus, Kubang Kerian, Kota Bharu, Kelantan, Malaysia, Kota Bharu, Malaysia

⁶ Department of Conservative Dentistry & Endodontics, Saveetha Dental College & Hospitals, Saveetha Institute of Medical and Technical Sciences University, Chennai, Tamil Nadu, India

- ⁷ Department of Clinical Science, College of Dentistry, Ajman University, Al-Jurf Ajman, UAE
- ⁸ Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, UAE

⁹ Department of Conservative Dentistry & Endodontics, Nair Hospital Dental College, Mumbai, Maharashtra, India, Mumbai, India

ABSTRACT

Objective. The goal of this systematic review and meta-analysis is to determine the performance of 4% Articaine *vs.* 2% Lidocaine for mandibular and maxillary block and infiltration anaesthesia in patients with irreversible pulpitis (IP).

Methods. PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, Web of Science, Google Scholar, and Open Gray were used to conduct a thorough literature search. A manual search of the reference lists of the publications found was also carried out. Two reviewers critically evaluated the papers for inclusion and exclusion criteria, and data extraction was done on the selected publications. The Cochrane Collaboration Tool and the Minors checklist were used to assess the quality of the selected studies for randomised controlled trials (RCTs) and non-randomised studies, respectively. The RevMan software was used to perform a meta-analysis of the pooled data and subgroups according to the technique of anaesthetic solution delivery, as well as a sensitivity analysis (P < 0.05).

Results. A total of twenty-six papers were included in the qualitative synthesis, with twenty-two of them being included in the meta-analysis. There were fifteen studies with a low potential for bias, three with a moderate potential for bias, and seven with a high potential for bias. The combined results of the 19 trials in the tooth level unit revealed

Submitted 12 May 2021 Accepted 5 September 2021 Published 24 September 2021

Corresponding authors Alexander Maniangat Luke, a.luke@ajman.ac.ae Ajinkya M. Pawar, ajinkya@drpawars.com

Academic editor Luca Testarelli

Additional Information and Declarations can be found on page 25

DOI 10.7717/peerj.12214

Copyright 2021 Miglani et al.

Distributed under Creative Commons CC-BY 4.0

OPEN ACCESS

that 4% articaine had a success rate 1.37 times greater than 2% lidocaine for mandibular teeth (RR, 1.37; 95% CI [1.17–1.62]; P = 0.0002). For the maxillary buccal infiltration method, the combined results from the three trials revealed that 4% articaine resulted in a success rate 1.06 times greater than 2% lidocaine (RR, 1.06; 95% CI [0.95–1.2]; P = 0.3). Excluding subgroups with a single study in sensitivity analysis for mandibular teeth revealed a substantial improvement in the success rate of the articaine group in treating IP when compared to the lidocaine group.

Conclusion. The findings of this meta-analysis back up the claim that articaine is more effective than lidocaine in providing anaesthesia in patients with IP. PROSPERO Registration No.: CRD42020204606 (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020204606).

Subjects Dentistry

Keywords Articaine, Irreversible pulpitis, Lidocaine, Meta-analysis, Sensitivity analysis, Success rate

INTRODUCTION

Dental caries is the most widespread non-communicable disease and a major public health concern globally. It is also the most common preventable disease, recognised as the primary cause of oral pain and tooth loss (*World Health Organization, 2017*). Pulpitis is the inflammation of the dental pulp and a sequel to caries. It is clinically classified as reversible or irreversible (*Rôças et al., 2015*). Irreversible pulpitis (IP), usually develops when the pulp is exposed to caries biofilm causing necrosis or death of pulp tissues, indicating the need for endodontic treatment (*Li et al., 2012; Zanjir et al., 2019*).

Successful anaesthesia is a hallmark of painless endodontic treatment. It not only keeps the patient calm and relaxed but also allows the dentist to perform the endodontic procedure with ease (*Subbiya & Pradeepkumar, 2016*; *Howait & Basunbul, 2019*). Pulpal anaesthesia commences with the administration of traditional nerve blocks (NBs) or infiltration anaesthesia. For maxillary teeth, NB injections are administered at the anterior superior alveolar (ASA), middle superior alveolar (MSA), and/or posterior superior alveolar (PSA) nerves. For mandibular anterior teeth and molars, both the inferior alveolar nerve block (IANB) and buccal infiltration (BI) injections are administered (*Reader, Nusstein & Hargreaves, 2011*). Local anaesthetic (LA) drugs have a peripheral effect and block the transmission of nerve impulses. Factors that affect anaesthetic drug efficacy are the type of applied drug, correct injection site, injection velocity, and amount and dosage of the injected drug. Also, the presence of inflammation at the injection site should not be overlooked (*Modaresi et al., 2016*).

The success rate of achieving deep pulpal anaesthesia lowers in patients with IP. The success rate of IANB can be reduced to <30% (*Shahi et al., 2018*), and that of maxillary NBs to <60% (*Sherman et al., 2008*). It is broadly accepted that achieving anaesthesia in patients with IP is more complex, as compared to normal, healthy pulps (*Dou et al., 2013*; *Dou et al., 2018*). Inflamed pulp shows lower pH levels, lowering the penetration of basic anaesthetic into the nerve membrane, thus delaying or preventing pulpal anaesthesia

(*Zanjir et al., 2019*). This state of the tooth is frequently referred to as a 'hot pulp', which requires supplementary approaches to ensure a pain-free treatment (*Subbiya & Pradeepkumar, 2016*). Nonetheless, the effect of different anaesthetic agents and techniques along with or without supplemental infiltration needs to be assessed.

Lidocaine, the first commercialised amide LA solution shows rapid onset when used for most of the dental treatments and is considered as the gold standard LA agent due to its high efficacy, low allergenicity and minimal toxicity (*Su et al., 2016*). Articaine [(4methyl-3-[1-oxo-2-(propylamino)-propionamido]-2-thiophene-carboxylic acid methyl ester hydrochloride)] is a unique amide LA agent that contains a thiophene ring instead of a benzene ring, demonstrating increased liposolubility and high tissue penetrability as compared to lignocaine. The thiophene ring raises the diffusion of the anaesthetic solution into the cortical bone, thereby penetrating the mandibular dense cortical bone as well as maxillary cortical plates. Previous studies by *De Geus et al., (2020)* and *Srinivasan et al.* (2017) have also shown that articaine is equally effective in comparison to other anaesthetics with the success rate ranging from 64 to 87%.

Systematic reviews comparing the anaesthetic efficacy of articaine and lidocaine for dental procedures have been published. Kung, McDonagh & Sedgley (2015) concluded that articaine has a significant advantage over lidocaine as a supplementary infiltration after mandibular block anaesthesia but no advantage when used alone as mandibular block or maxillary infiltration anaesthesia. Su et al. (2016) stated that at the injection phase and treatment phase, 4% articaine is superior in controlling pain and increasing the success rate of local anaesthesia than 2% lidocaine. However, out of 24 articles included in that analysis, 20 articles were Chinese language reports which could not be accessed and retrieved from the databases by the authors of this review. Both the reviews described above were based on searches conducted until 2013. De Geus et al. (2020) in the network meta-analysis concluded that in patients with IP, the use of articaine increased the IANB success rate. This review considered the efficacy of IANB in patients with IP and did not include maxillary injection techniques as well as other supplemental techniques. A preliminary electronic database search revealed that since the publication of the above reviews, several new randomised clinical trials (RCTs) comparing articaine and lidocaine for patients with symptomatic IP have been published. Therefore, the present systematic review assessed the efficacy of 4% articaine vs 2% lidocaine in the mandibular and maxillary block and infiltration anaesthesia in patients with IP.

METHODS

Protocol development

This systematic review and meta-analysis are written and reported according to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statement and registered in PROSPERO (CRD42020204606). The following focused question in the Patient, Intervention, Comparison, and Outcome (PICO) format was proposed "Is there a difference in the efficacy of 4% articaine *vs* 2% lidocaine in the mandibular and maxillary block and infiltration anaesthesia in patients with IP?"

Table 1The search strategy and PICOS tool.

| Search strategy | |
|-----------------------|--|
| Focused | Is there a difference in the efficacy of 4% Articaine versus 2% Lidocaine in mandibular and maxillary block and in- |
| Question | filtration anaesthesia in patients with irreversible pulpitis? |
| Search strategy | |
| Population (#1) | ((Irreversible pulpitis [Text Word]) OR ("maxilla"[MeSH Terms] OR maxillary[Text Word]) AND ("tooth"[MeSH Terms] OR teeth[Text Word]) OR ("mandible"[MeSH Terms] OR mandibular[Text Word]) AND ("tooth"[MeSH Terms] OR teeth[Text Word]) OR lower teeth [Text Word] OR upper teeth [Text Word] OR "molar"[MeSH Terms] OR molar[Text Word] OR posterior teeth [Text Word] OR anterior teeth [Text Word] OR premolar [Text Word] OR "incisor"[MeSH Terms] OR incisor[Text Word] OR canine [MeSH])) |
| Intervention (#2) | ((Articain [Text Word] OR Articaine [Text Word] OR Carticaine [MeSH] OR Carticaine Hydrochloride [Text Word] AND (Local Anesthesia [Text Word] OR Infiltration Anesthesia [Text Word] OR nerve block [Text Word] OR inferior alveolar nerve block [Text Word] OR buccal infiltration [Text Word] OR Infra-orbital nerve block [Text Word] OR Anterior superior nerve block [Text Word] OR Middle superior nerve block [Text Word])) |
| Comparisons (#3) | ((Lidocaine [MeSH] OR Lidocaine Hydrochloride [Text Word] OR Lignocaine [Text Word]) AND (Local Anes- thesia [Text Word] OR Infiltration Anesthesia [Text Word] OR nerve block [Text Word] OR inferior alveolar nerve block [Text Word] OR buccal infiltration [Text Word] OR Infra-orbital nerve block [Text Word] OR Anterior su- perior nerve block [Text Word] OR Middle superior nerve block [Text Word])) |
| Outcomes (#4) | (Success [Text Word] Pain [Text Word] OR onset time [Text Word] OR duration [Text Word] OR Visual analogue scale [MeSH] OR Heft Parker Visual Analog Scale [Text Word]) |
| Study design (#5) | (Clinical trials [MeSH] OR randomized controlled studies [Text Word] OR randomized control trials [MeSH] OR randomized control clinical trial MeSH OR non-randomized control trials [Text Word] OR Quasi experimental studies [Text Word] OR before and after study design [Text Word] OR cohort studies [Text Word] OR in vivo study [Text Word]) |
| Search combination | #1 AND #2 AND #3 AND #4 AND #5 |
| Database search | |
| Language | No restriction (Articles in English language or other language where English translation is possible.) |
| Electronic databases | PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, Web of Science |
| Journals | Journal of Endodontics, International Endodontic Journal, Australian Endodontic Journal, Clinical Oral Investiga- tions, Journal of Conservative Dentistry, Journal of American Dental Association |
| Period of publication | Studies published between 1-1-2011 to 30-09-2020 |

Search strategy

To obtain publications in the English language, a complete electronic search was conducted through July 2020 on databases such as PubMed and MEDLINE, Cochrane Central Register of Controlled Trials, and Web of Science. A detailed electronic search of the journals listed in Table 1 was carried out. The searches in the clinical trials database, cross-referencing and Grey literature were conducted using Google Scholar, Greylist, and OpenGrey.

Articles were found using Medical Subject Headings (MeSH) terms, keywords, and other free terms coupled with Boolean operators (OR, AND). Following the syntactic guidelines of each database, the same terms were utilised across all search platforms. Table 1 shows the search strategy, population, interventions, comparisons, outcomes, and study design (PICOS) tool.

Inclusion criteria outline according to the PICOS strategy

Population (P):

Studies on patients with symptomatic IP, requiring endodontic treatment under maxillary and mandibular infiltration or blocked anaesthesia on at least one tooth in

the mandibular or maxillary region irrespective of age, gender, race, or socioeconomic status, were evaluated. Active responses to spontaneous pain, thermal tester, cold tester, or an electronic pulp tester were considered as diagnostic criteria for IP.

Interventions (I): Studies using 4% articaine as a LA solution for the treatment of IP.

Comparison (C): Studies using 2% lidocaine as a LA solution for the treatment of IP.

Outcome (O): Primary outcome: It included the success rate assessed as 'no/mild' pain during access cavity preparation and biomechanical preparation phase on the Heft Parker visual analogue scale (VAS).

Secondary outcome: Onset of anaesthesia assessed from the time lapse between the end of the NB and the onset of symptoms of subjective anaesthesia (feeling of heaviness at the site of injection) were calculated in seconds, and the pain was assessed quantitatively during the treatment.

Study design (S): In vivo studies, clinical trials, RCTs, cluster randomised trials, quasiexperimental studies and non-randomised trials (NRS).

Exclusion criteria

- Studies involving patients with a significant medical history or on medicaments that may affect the anaesthetic assessment.
- Observational study designs, case reports, case series, cross-sectional studies, and reviews.
- Trials reporting a single intervention.
- Article reporting only abstracts and full-texts were not available in the database.

Screening process

Two reviewing authors did the search and screening according to the previously stated methodology (SP & AM). The titles and abstracts were examined first. Second, full-text publications were picked for in-depth reading and analysis based on the data extraction criterion's inclusion and exclusion criteria. Cohen's kappa (k) determined the degree of agreement between the two reviewers to be 0.94 for titles and abstracts and 0.96 for full-texts. After discussions, the third author SM was able to reconcile the disagreements among the authors/reviewers. The authors of the listed papers were contacted *via* email for clarification of any concerns or missing data.

Data extraction

The two independent authors (IA & BA) extracted the following data from the included studies: author names, study design, tooth, sample size, method of pulp testing, type of local anaesthesia used, injection technique, method of analysis, method of outcome assessment, follow-up and author's conclusions.

Assessments of the risk of bias and quality

The level of evidence for included studies was assessed using the Joanna Briggs Institute (JBI) level of evidence (*The Joanna Briggs Institute*, 2014). The quality of the selected studies was assessed using the Cochrane Collaboration Tool (*Higgins et al.*, 2019) for RCTs, including random sequence generation, allocation concealment, blinding of participants,

incomplete outcome data, selective reporting, and other biases. The quality of NRS was assessed using the Minors checklist (*Slim et al., 2003*), wherein the minimum outcome assessment time of 5 min was considered appropriate for the included studies.

Statistical analysis

Review Manager (RevMan) 5.3 was used for statistical analysis. The combined results were expressed as relative risks (RRs) for the dichotomous data at 95% confidence intervals (CIs) and P < 0.05 was considered significant. Statistical heterogeneity was assessed by the I² test at $\alpha = 0.10$. Subgroup analysis was conducted for I² > 50% and $P \le 0.10$. For I² > 50%, the random-effects model was applied. Sensitivity analysis was conducted to assess the stability of the results. Funnel plots were drawn to detect publication bias for studies exceeding 10 in number for each outcome assessed (*Su et al., 2016*).

RESULTS

Literature search

The PRISMA statement flowchart summarising the selection process is presented in Fig. 1. Among 33 full-text articles, 26 were selected after pre-screening, applying the eligibility criteria, and addressing the PICOS question. Seven studies were excluded as three did not have a control group, three had inappropriate population variables, and one applied intraosseous injection technique, hence only 26 studies were included in the qualitative analysis, whereas 22 out of 26 studies for quantitative synthesis.

Study characteristics

The general characteristics of 26 studies (Gao & Meng, 2020; Kumar et al., 2020; Aggarwal et al., 2019; Ghazalgoo et al., 2018; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani, 2017; Umesh, 2017; Allegretti et al., 2016; Hosseini et al., 2016; Saraf et al., 2016; Zain et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Ahmad et al., 2014; Nabeel, Ahmed & Sikander, 2014; Rogers et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Tortamano et al., 2013; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b; Aggarwal et al., 2011; Poorni et al., 2011) are presented in Table 2. All included studies were unicentric trials published between 2011 and 2020. Of the 26 studies, 10 studies (Kumar et al., 2020; Aggarwal et al., 2019; Lokhande et al., 2019; Aggarwal, Singla & Miglani, 2017; Umesh, 2017; Saraf et al., 2016; Sood, Hans & Shetty, 2014; Subbiya et al., 2011; Aggarwal et al., 2011; Poorni et al., 2011) were conducted in different parts of India, 3 in Iran (Ghazalgoo et al., 2018; Hosseini et al., 2016; Ashraf et al., 2013), Pakistan (Zain et al., 2016; Rajput et al., 2015; Nabeel, Ahmed & Sikander, 2014) and Brazil (Allegretti et al., 2016; Monteiro et al., 2015; Tortamano et al., 2013), 2 in the USA (Shapiro et al., 2018; Rogers et al., 2014), 2 in the UK (Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b) and one each in China (Gao & Meng, 2020), Colombia (Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018) and Saudi Arabia (Ahmad et al., 2014). The study design of 24 studies (Gao & Meng, 2020; Kumar et al., 2020; Aggarwal et al., 2019; Ghazalgoo et al., 2018; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani,



2017; Umesh, 2017; Allegretti et al., 2016; Hosseini et al., 2016; Saraf et al., 2016; Zain et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Nabeel, Ahmed & Sikander, 2014; Rogers et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b; Aggarwal et al., 2011; Poorni et al., 2011) was RCTs, and the remaining 2 studies (*Ahmad et al., 2014; Subbiya et al., 2011*) were NRS. The age of the participants was 15–65 years. The ethical clearance and informed consent were obtained in all except 2 studies (*Lokhande et al., 2019; Subbiya et al., 2011*). A total of 1,824 teeth with completely formed root apex, diagnosed with symptomatic IP and anaesthetised with either articaine or lidocaine were included in the review, 1,578 mandibular teeth from 22 studies (*Gao & Meng, 2020; Kumar et al., 2020; Aggarwal et al., 2019; Ghazalgoo et al., 2018; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani, 2017; Umesh, 2017; Allegretti et al., 2016; Zain et al., 2016; Monteiro et al., 2013; Tortamano et al., 2013; Kanaa, Whitworth & Meechan, 2012b; Subbiya et al., 2011; Asgarwal et al., 2011; Poorni et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Tortamano et al., 2013; Kanaa, Whitworth & Meechan, 2012b; Subbiya et al., 2011; Poorni et al., 2011; Poorni et al., 2011) and 246 maxillary*

teeth from 4 studies comprised the present meta-analysis (*Hosseini et al., 2016; Saraf et al., 2016; Nabeel, Ahmed & Sikander, 2014; Kanaa, Whitworth & Meechan, 2012a*) (Table 2).

A significant methodological heterogeneity was observed between the studies. This could be attributed due to the differences in the anatomic location of the teeth being anaesthetized (mandible (Gao & Meng, 2020; Kumar et al., 2020; Aggarwal et al., 2019; Ghazalgoo et al., 2018; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani, 2017; Umesh, 2017; Allegretti et al., 2016; Zain et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Ahmad et al., 2014; Rogers et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Tortamano et al., 2013; Kanaa, Whitworth & Meechan, 2012b; Subbiya et al., 2011; Aggarwal et al., 2011; Poorni et al., 2011) or maxilla (Hosseini et al., 2016; Saraf et al., 2016; Nabeel, Ahmed & Sikander, 2014; Kanaa, Whitworth & Meechan, 2012a), anterior (Saraf et al., 2016; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b) or posterior (Gao & Meng, 2020; Kumar et al., 2020; Aggarwal et al., 2019; Ghazalgoo et al., 2018; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani, 2017; Umesh, 2017; Allegretti et al., 2016; Hosseini et al., 2016; Saraf et al., 2016; Zain et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Ahmad et al., 2014; Nabeel, Ahmed & Sikander, 2014; Rogers et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Tortamano et al., 2013; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b; Aggarwal et al., 2011; Poorni et al., 2011), tooth type (molars Gao & Meng, 2020; Kumar et al., 2020; Aggarwal et al., 2019; Ghazalgoo et al., 2018; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani, 2017; Umesh, 2017; Allegretti et al., 2016; Hosseini et al., 2016; Zain et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Ahmad et al., 2014; Rogers et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Tortamano et al., 2013; Kanaa, Whitworth & Meechan, 2012b; Subbiya et al., 2011; Aggarwal et al., 2011; Poorni et al., 2011, premolars (Saraf et al., 2016; Nabeel, Ahmed & Sikander, 2014; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b) or anterior teeth (Saraf et al., 2016; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b)), volume of anaesthetic solution administered during the intervention (0.6 mL (Aggarwal et al., 2019), 0.9 mL (Gao & Meng, 2020), 1.7 mL (Shapiro et al., 2018; Rajput et al., 2015; Nabeel, Ahmed & Sikander, 2014; Rogers et al., 2014; Subbiya et al., 2011), 1.8 mL (Kumar et al., 2020; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Aggarwal, Singla & Miglani, 2017; Hosseini et al., 2016; Zain et al., 2016; Monteiro et al., 2015; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Tortamano et al., 2013; Aggarwal et al., 2011; Poorni et al., 2011), 2.0 mL (Lokhande et al., 2019; Saraf et al., 2016; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b), 3 mL (Umesh, 2017), 3.6 mL (Allegretti et al., 2016) and 6 mL (Umesh, 2017)), concentration of epinephrine in articaine and lidocaine and delivery route of the anaesthetic solution. Interestingly, the anaesthetic solutions for mandibular teeth were delivered via IANB (Kumar et al., 2020; Ghazalgoo et al., 2018; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Aggarwal, Singla & Miglani, 2017; Umesh, 2017; Allegretti et al., 2016; Ahmad et al., 2014; Sood, Hans & Shetty, 2014; Tortamano et al., 2013; Poorni et al., 2011), BI (Hosseini et al.,

| Study Id | Place of study | Study Design | Sampling Technique | Sample Size Intervention /Control | Age group in years Intervention /Control Mean(SD) or Range | Gender M/F Intervention /Control N | Teeth assessed | Pulp testing | Periapical radiolucency/ widened periodontal ligament | Anaesthetic solution | | Anaesthesia technique | | Solution dosage in | | Recording time in minutes | Outcome assessed | Authors conclusions |
|----------------------------|-------------------|--|---|--|---|---|--|--|---|--|---|---|---|-----------------------|---------------|---------------------------------|---|--|
| | | | | | | | | | | Intervention group | Control group | Intervention group | Control group | Intervention group | Control group | _ | | |
| Gao & Meng (2020) | China | Prospective, randomised clinical study | Random num- bers table | 52/52 | 39.2(13.2)/ 40.1(12.9) | 24 M, 28 F/ 22 M, 30 F | Mandibular posterior teeth | Electric pulp test Cold test. | No/- | 4% Articaine with 1:100,000 adrenaline | 2% Lidocaine with 1:100,000 adrenaline | Supplementary intraligamentary BI after IANB failure | Supplementary intraligamentary BI after IANB failure | 0.9 | 0.9 | 5 | Success of anaesthesia | Supplemental Bl with Arti- caine following IANB can be considered a more suc- cessful aneas- thetic agent in mandibular posterior teeth with irreversible publitis com- pared with lidocaine |
| Kumar et al. (2020) | India | Double blind randomized clinical study | Randoy as- signed | 13/ 12 | 1555 | - | Symptomatic mandibular posterior teeth | Thermal tests with endo frost and heated gutta- percha sticks Electric pulp test | No/Yes | 4% Articaine with 1:100,000 Epinephrine | 2% Lido- caine; 1:80,000 Epinephrine | IANB | IANB BI | 1.8 | 1.8 | 15 | IANB success BI Success | Overall success rate with 4% Articaine was 92% and with 2% Lidocaine was 75% after IANB and BI. |
| Aggarwal et al. (2019) | India | Randomized, double- blind clinical trial | Online random generator using a permuted block stratified randomization | 41/41 | 37(8) / 34(9) | 24 M 17 F/ 27 M 14 F | Symptomatic mandibular molars | Cold tests Electric pulp tests | No/- | 4% Articaine with 1:100,000 epinephrine | 2% Lido- caine with 1:80,000 epinephrine | Supplementary intraligamentary injections after IANB failure | Supplementary intraligamentary injections after IANB failure | 0.6 | 0.6 | 5 | Success of anaesthesia | 2% lidocaine with 1:80,000 epinephrine and 4% Ar- ticaine with 1:100,000 epinephrine as supplementary intraligamen- tary injections after an unsuc- cessful primary IANB improved the success rates, with no significant dif- ference between them. |
| Ghazalgoo et al. (2018) | Iran | Prospective double-blind clinical trial study | Random | 44/44 | - | - | Symptomatic mandibular first molar | Cold test | - | 4% Arti- caine with 1:100,000 epinephrine | 2% Lido- cainewith 1:100,000 epinephrine | IANB | IANB | - | - | 15 | Pain levels at 0, 2, 4, 6, 12, 18, 36, and 48 h | Articaine for IANB may increase post- root canal treat- ment comfort than lidocaine |
| Lokhande et al. (2019) | India | Single blinded randomized clinical trial | Convenience | 30/30 | Above 18 years | - | Symptomatic mandibular molar | - | No/- | 4% Articaine (1:100000 adrenaline) | 2% Lido- caine (l:80000 adrenaline) | BI combined with intraliga- mentary injec- tion | BI combined with intraliga- mentary injec- tion | 1.8 + 0.2 | 1.8 + 0.2 | 5 | Anaesthesia success | BI with 4% Articaine along with supplemental injection (in- traligamen- tary) increased anaesthetic success rates. |

 Table 2
 Characteristics of the included studies.

(continued on next page)

| Study Id | Place of study | Study Design | Sampling Technique | Sample Size Intervention /Control | Age group in years Intervention /Control Moon(SD) =: | Gender M/F Intervention /Control N | Teeth assessed | Pulp testing | Periapical radiolucency/ widened periodontal | Ana so | esthetic lution | Ana tecl | esthesia hnique | So dos | lution sage in | Recording time in minutes | Outcome assessed | Authors conclusions |
|---|-------------------|---|---|--|--|---|--|--|---|--|---|---|---|--|--|---------------------------------|--|---|
| | | | | | Range | | | | ngament | Intervention group | Control group | Intervention group | Control group | Intervention group | Control group | _ | | |
| Martínez- Martínez, Freyle- Granados & Senior- Carmona (2018) | Colombia | Randomized, double-blind, parallel- controlled clinical trial | Block random- ization | 18/18 | Over 18 | - | Lower molars | Vitalometer | - | 4% Articaine with 1:100,000 epinephrine | 2% Lidocaine with 1:80,000 epinephrine | IANB | IANB | 1.8 | 1.8 | 10 | Anaesthesia success | No statisticall significant differences we found in the anaesthetic efficacy of 2% lidocaine and 4% Articaine in lower mo- lars with vital pulp. Articain showed a bett anaesthetic success rate. |
| apiro et al. 018) | United States | Prospective, randomized, double-blind | Block random- ization | 76/73 | 37-41 | 41 M, 35 F/ 32 M, 41 F | Symptomatic mandibular molar | Cold testing with Endo-Ice | No/Yes | 4% Articaine with 1:100,000 epinephrine | 2% Lido- caine with 1:100,000 epinephrine | Supplementary Bl after IANB failure | Supplementary BI after IANB failure | 1.7 | 1.7 | 5 | Successful infiltration anaesthesia | Supplemental BI with 4% Articaine and 2% lidocaine was found to have compara ble success in the first molar region. BI wit 4% Articaine was signifi- cantly more effective than 2% lidocaine for mandibul second molar with irreversil pulpitis. |
| ggarwal, ingla & figlani 2017) | India | Prospective, double-blind clinical study | Randomized using an on- line random generator | 32/31 | 34(6.5)/ 37(8.3) | 16 M, 14F/ 22 M, 9F | Mandibular molar | Pulp sensitivity tests | No/- | 4% Articaine with 1:100,000 epinephrine | 2% Lidocaine with 1:200,000 epinephrine | IANB | IANB | Standard 4% Articaine cartridge/ 1.8 mL | 1.8 | 15 | Success of anaesthesia | The 2% lido- caine solution used for IANI had similar su cess rates whe compared wit 4% Articaine |
| inesh 1000) | India | Prospective, randomized, triple-blind study | Randomly- Sequence generated by computerized permutted block | 30/30 | 18-65 | - | Symptomatic mandibular molars | Electric pulp test Thermal test | - | 4 % Arti- caine with 1:1 , 00,000 Adrenaline | 2% Ligno- caine with 1: 80,000 Adrenaline | IANB | IANB | 6 | 3 | - | Pre-post- operative pain | 4% articaine + 1:1,00,000 epinephrimed better than 2% lignocaine + 1:80,000 epinephrine in reducing pain during endodontic access openin and instrume tation. |
| llegretti et . (2016) | Brazil | Prospective, randomized, double-blind clinical study | Simple random | 22/22 | 28.7/ 30.3 | 10 M, 12 F/ 9 M, 13 F | Symptomatic first or second molars | Electric pulp test Cold testing with Endo- Frost | No/- | 4% Articaine with 1:100,000 epinephrine | 2% Lidocaine with 1:100,000 epinephrine | Standard IANB | Standard IANB | 3.6 | 3.6 | 14 to 16 | Success of anaesthesia | Neither of the solutions re- sulted in 1009 anaesthetic su cess in patient with irreversal pulpitis of mandibular molars. |
| vsseini et (2016) | Iran | Prospective, randomized double-blind study | Simple random | 25/25 | - | - | Asymptomatic first maxillary molar | Eelectric Pulp Tester Cold tests | No/- | 4% Articaine with 1:100000 epinephrine | 2% Lidocaine with 1:80000 epinephrine | BI | Ы | 1.8 | 1.8 | 5 | Success of anaesthesia | The type of anaesthetic solution had no significant influence on the success rat of anaesthesia with Articaine and lidocaine being similarh effective. |
| raf et al. 016) | India | Clinical study | Random | 20/20 | - | - | Symptomatic maxillary ante- riors and premo- lars | Electric pulp tester | - | Group I: Ar- ticaine HCl 4% with 1:100,000 adrenaline Group II: Ar- ticaine HCl 4% with 1:100,000 adrenaline | Group III: Lidocaine HCl 2% with 1:80,000 adrenaline Group IV: Lidocaine HCl 2% with 1:80,000 adrenaline | Group I: An- terior middle superior alveo- lar nerve block Group II: In- fraorbital nerve block | Group III: Anterior middle superior alveo- lar nerve block Group IV: Infraorbital nerve block | Group I: 0.6–1.4 Group II: 0.9– 1.2 | Group III: 0.6–1.4 Group IV: 0.9– 1.2 | 30 | Onset of anaesthesia Pain assessment | Articaine 4% proved to be more effica- cious than lidocaine 2%, and AMSANT was more advantageous than IONB in securing anaesthesia of maxillary anteriors and premolars |
| Tain et al. 2016) | Pakistan | Prospective and randomized clinical trial | Lottery method | 78/78 | 31.46(10.99) | 46 M, 32 F/ 46M, 32 F | Symptomatic mandibular 1st molar | yes | No/- | 4% Articaine with 1:100,000 epinephrine | 2% lido- caine with 1:100,000 | Ы | IANB | 1.8 | 1.8 | 10 | Success of anaesthesia | 4% Articaine can be consid ered a viable <i>e</i> ternative to 2 ^t lidocaine IAN in securing su cessful pulpal anaesthesia fo endodontic |

Table 2 (continued)

Place of study

Study Design

Sampling Technique

Gender M/F

Teeth assessed

Pulp testing

Anaesthetic

solution

Anaesthesia

technique

Solution dosage in

Recording time in minutes

Outcome

assessed

Authors conclusions

Study Id

Nabee

& Shetty

(2014)

Sample Size Intervention /Control Age group in years Intervention /Control Mean(SD) or Range Periapical radiolucency/ widened periodontal ligament Intervention /Control Intervention Control group Intervention Control group Intervention Control group group Prospective and randomized 5 M, 25 F/ 4 M, Cold tests 1.8 Brazil Random num-30/20 28(13.8)/ No/ Yes 4% Arti-2% Lidocaine BIs IANB injections 1.8 10 Single anaesthe Monteiro et Symptomatic Success of caine with 1: 100 000 epinephrine sia techniques (IANB or BI) were not able to achieve painal. (2015) bers 33,5(16,5) 16 F mandibular with 1: 100 000 anaesthesia clinical trial molars epinephrine free emergency endodontic treatment. Rajput et al. (2015) Pakistan Prospective, randomized clinical trial Simple ran domized 30/30 18-65 Symptomatic mandibular first molar 4% Arti-caine with 1:100,000 2% Lido-caine with 1:200,000 Standard BI Standard IANB 1.7 1.8 10 Success of anaesthesia 4% Articaine with 1:100,000 epinephrine can be considered epinephrine epinephrine as an alternative for pulpal anaesthesia in mandibular first molar with irreversible pulpitis. 4% Articaine with 1:100000 2% Lidocaine with 1:200000 4% Articaine with 1:100,000 Ahmad et al. (2014) Riyadh, Saudi Non-randomized 15/15 18 - 40Symptomatic mandibular teeth Cold No Standard IANB Standard IANB 15 Success of anaesthesia testing with Arabia control trial an ice stick Electric pulp tester epinephrine epinephrine epinephrine showed better anaesthetic effect when administered as inferior alveolar nerve block as compared to 2% lidocaine with 1:200,000 epinephrine. Computer-generated list of random numbers Pakistar 15 M, 23 F/ 18 Maxillary first 2% Lidocaine BI BI 1.7 1.7 5 Successful The anaesthetic Randomized 38/38 4% Atricaine Ahmed & Sikander (2014) efficacy of Articaine is comparable to that of Lidoclinical trial M, 20 F premolars with 1:100.000 with 1:100.000 infiltration epinephrine epinephrine anaesthesia caine in subjects with acute irreversible pulpitis of maxillary teeth with irreversible pulpitis. Cold testing with Endo-Ice 2% Lido-caine with 1:100,000 Supplemental BI with Arti-caine was sig-nificantly more 17 M, 22 F / 12 M, 23 F 4% Articaine with 1:100,000 Successful infiltration Rogers et al. (2014) Prospective, double-blind Block random-39/35 36(14)/36(12) Symptomatic mandibular No/Yes Supplementar BI after IANB Supplementary BI after IANB 1.7 1.7-5 United States ization randomized, molar epinephrine failure failure anaesthesia controlled epinephrine clinical trial effective than Lidocaine. India Prospective, randomized, 50/50 26.46/28.90 20 M/30 F, Mandibular Electric pulp No/Yes 4% Articaine 2% Lidocaine IANB IANB 1.8 1.8 10 Absence/presence No difference Sood, Hans Not mentioned 27 M/23 F posterior teeth testing with 1:100.000 with 1:80,000 of pain in the efficacy double-blind epinephrine epinephrine of both the Cold testing using Roeko Endo-Frost of both the dental anaes-thetic agents in controlling clinical study pain during the treatment of irreversible pulpitis. Symptomatic first or second mandibular molar Ashraf et al. (2013) Prospective, randomized, double-blind 37.9 (10.0)/ 24 M,27 F/ Cold testing No/Yes 2% Lido-Standard IANB Standard IANB 1.5 + 0.31.5 + 0.35 Successful Iran Randomized 58/58 4% Articaine Articaine seems using random allocation software 32.5 (8.7) 23 M, 28 F by using an ice stick with 1:100,000 caine with 1:100,000 and long buccal injections and long buccal injections infiltration to raise anaes-thetic success more effectively epinephrine anaesthesia epinephrine study compared with lidocaine after an incomplete IANB is sup-plemented with an infiltration injection by using the same anaesthetic for both injections in teeth with irreversible pulpitis.

(continued on next page)

Table 2 (continued)

| Study Id | Place of study | Study Design | Sampling Technique | Sample Size Intervention /Control | Age group in years Intervention /Control Mean(SD) or | Gender M/F Intervention /Control N | Teeth assessed | Pulp testing | Periapical radiolucency/ widened periodontal ligament | Anaesthetic solution | | Ana tec | esthesia hnique | Se de | olution osage in | Recording Outcome time in assessed minutes | Outcome assessed | Authors conclusions |
|--|---------------------|---|---|---|---|---|--|--|---|---|---|--|---|---|---------------------|--|--|---|
| | | | | | Range | | | | ngament | Intervention group | Control group | Intervention group | Control group | Intervention group | Control group | _ | | |
| Tortamano et al. (2013) | Brazil | Prospective, randomized, double-blinded clinical study | Random | 20 (10 each)/ 10 | - | - | Asymptomatic mandibular posterior molars | Electric pulp stimulator | No/- | ART1100– 4% Articaine with 1:100,000 epinephrine | 2% lidocaine with 1:100,000 epinephrine | IANB | IANB | 1.8 | 1.8 | 10 | Onset of pulpal anaesthesia | 4% Articaine with 1:100,000 epinephrine exhibited faster onset and also had longest duration of pulpal anaes- thesia when compared with all solutions |
| Kanaa, Whitsworth & Meechan (2012a) | United King- dom | Double-blind randomized trial | Web-based program for randomization | 38/35 | Over 16 years | | Maxillary perma- nent teeth | Electronic pulp tester | - | 4% Articaine with 1:100,000 epinephrine | 2% lidocaine hydrochloride and epinephrine 1:80,000 | Ы | ВІ | 2 | 2 | 10 | Succesful infiltration anaesthesia | BIs with 4% Articaine with 1:100,000 epinephrine and 2% ii- docaine with 1-docaine with 1-docaine with 1-docaine with 1-docaine with 1-docain |
| Kanaa, Whitworth & Meechan (2012b) | United King- dom | Double-blind randomized trial | Web-based program for randomization | 25/25 | 18 or older | - | Mandibular teeth | Electronic pulp tester | - | 4% Articaine HCL with epinephrine 1:100,000 | 2% Lidocaine HCL with 1:80,000 epinephrine | Supplementary BI after IANB failure | Repeat lido- caine IANB after IANB failure | 2.0 | 2.0 | 5 | Successful infiltration anaesthesia | BI of 4% Ar- ticaine with epinephrine allowed more pain-free treatments than repeat LANB injections for patients experiencing irreversible publitis in mandibular permanent teeth. |
| Subbiya et al. (2011) | India | Clinical study | Non- random | 30/30 | 37 years | - | Symptomatic mandibular first molar | Cold testing with an ice stick Electric pulp tester | No/- | 4% Arti- caine with 1:2,00,000 adrenaline | 2% Lignocaine with 1:2,00,000 | BI injection | IANB | 1.7 | 1.7 | 15 | Aesthetic success | 4% Articaine with 1:1,00,000 adrenaline can be considered as an alternative for anesthetis- ing mandibular first molar instead of IANB with 2% lignocaine with 1:2,00,000 adrenaline. |
| Aggarwal et al. (2011) | India | Prospective, randomized, double-blind study | Simple random generator | 24/24 | 31/ 30.4 | 11 M, 13 F/ 12 M, 11 F | Mandibular molar | Cold test- ing with an ice stick and an electric pulp tester | No/Yes | 4% Articaine with 1:100,000 ephinephrine | 2% Lidocaine with 1:200,000 epinephrine | IANB plus BI | IANB injections | Standard 4% Articaine car- tridge | 1.8 | 15 | Pre-post- operative pain Success of anaesthesia | Supplemental infiltrations of Articaine along with conventional IANB, can be a useful adjunct in management of odontogenic pain in irre- versible pulpitis |
| Poorni et al. (2011) | India | Randomized double-blind clinical trial | Simple ran- domization | Test arm A 52 Test arm B 52 Test arm C 52 | Test arm A 24.40 (4.19) Test arm B 23.46(3.7) Test arm C 24.13(4.21) | Test arm A 28 M 24 F Test arm B 30 M, 32 F Test arm C 32 M, 20 F | Symptomatic Mandibular molars | Cold testing with an ice stick Electric pulp tester | No/Yes | 4% Articaine with 1:100,000 epinephrine | 2% Lidocaine with 1:100,000 | Test arm A IANB with 4% Articaine Test arm B Bl with 4% Articaine | Test arm C IANB with 4% Lidocaine | 1.8 | 1.8 | 20 | Successful anaesthesia | There is no statistically significant difference among IANB and infiltration of Articaine when compared with IANB of lidocaine in mandibular molars with irreversible pulpitis. |

Notes. BL BI: JANB Inferior 2016; Zain et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Nabeel, Ahmed & Sikander, 2014; Subbiya et al., 2011; Poorni et al., 2011), supplementary BI after IANB failure (Gao & Meng, 2020; Shapiro et al., 2018; Rogers et al., 2014; Kanaa, Whitworth & Meechan, 2012b), BI combined with intraligamentary injection (Lokhande et al., 2019), supplementary intraligamentary injections after IANB failure (Aggarwal et al., 2019), standard IANB and long Bis (Ashraf et al., 2013) and IANB plus BI (Aggarwal et al., 2011) and for maxillary teeth via BI (Kanaa, Whitworth & Meechan, 2012a), anterior middle superior alveolar nerve block (AMSA) (Saraf et al., 2016) and infraorbital nerve block (IONB) (Saraf et al., 2016). In nineteen studies, both the anaesthetic solutions were administered by the same dentist. (Gao & Meng, 2020; Kumar et al., 2020; Ghazalgoo et al., 2018; Lokhande et al., 2019; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani, 2017; Umesh, 2017; Allegretti et al., 2016; Zain et al., 2016; Ahmad et al., 2014; Rogers et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b; Aggarwal et al., 2011; Poorni et al., 2011) (Table 2).

The outcome parameters assessed post-intervention varied across studies. The success of pulpal anaesthesia assessed by VAS on a 4-point Likert scale or on a measured scale as no/mild pain during root canal treatment (endodontic access and pulpectomy) after administration of local anaesthesia, whereas the postoperative pain was assessed by the corresponding pain score on the numerical scale (Shapiro et al., 2018; Saraf et al., 2016; Zain et al., 2016; Rogers et al., 2014; Subbiya et al., 2011). The onset of anaesthesia was assessed from the time lapse between the end of NB and the onset of symptoms of subjective anaesthesia, such as the feeling of heaviness at the site of injection and lip numbness, or by electric pulp testing, cold testing, pulp evaluation and canal preparation using a standard digital stop clock. For the mandibular region, 19 studies assessed the success rate of anaesthesia (Gao & Meng, 2020; Kumar et al., 2020; Aggarwal et al., 2019; Ghazalgoo et al., 2018; Lokhande et al., 2019; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani, 2017; Allegretti et al., 2016; Zain et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Ahmad et al., 2014; Rogers et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Kanaa, Whitworth & Meechan, 2012b; Subbiya et al., 2011; Aggarwal et al., 2011; Poorni et al., 2011), 4 studies evaluated the postoperative pain (Umesh, 2017; Zain et al., 2016; Rogers et al., 2014; Aggarwal et al., 2011) and 1 study evaluated the mean onset time of anaesthesia (Tortamano et al., 2013). For the maxillary region, the success rate of anaesthesia was reported by 3 studies (Hosseini et al., 2016; Nabeel, Ahmed & Sikander, 2014; Kanaa, Whitworth & Meechan, 2012a), 1 study (Saraf et al., 2016) reported postoperative pain and 2 studies reported (Saraf et al., 2016; Kanaa, Whitworth & Meechan, 2012a) the mean onset time of anaesthesia. The recording time after LA injection ranged from 5–30 min in all the included studies, except in one (Umesh, 2017), which did not mention the time. VAS was used to assess the outcome in all studies except that the verbal analogue scale was applied by Allegretti et al. (2016) and the study by Tortamano et al. (2013) calculated the onset of pulpal anaesthesia in minutes. Overall, post-intervention results showed improvements in the intervention groups based on the outcome parameters (Gao & Meng, 2020; Kumar et al., 2020; Ghazalgoo et

al., 2018; Lokhande et al., 2019; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani, 2017; Umesh, 2017; Hosseini et al., 2016; Saraf et al., 2016; Zain et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Ahmad et al., 2014; Nabeel, Ahmed & Sikander, 2014; Rogers et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Tortamano et al., 2013; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b; Aggarwal et al., 2011; Poorni et al., 2011).

The mandibular postoperative pain assessed by *Ghazalgoo et al. (2018)*, *Umesh (2017)*, *Zain et al. (2016)*, *Rogers et al. (2014)* and *Aggarwal et al. (2011)* using Heft Parker VAS did not show a statistically significant difference between the two groups. The time point for outcome measurement and the outcomes of interest, based on the scoring criteria, were different; also, the method of delivery of the anaesthetic solution varied in each of the included studies. Thus, these were precluded from the meta-analysis, and only qualitative analysis was conducted (Table 2).

The study by *Saraf et al.* (2016) concluded that 4% articaine was more efficacious than 2% lidocaine, and AMSANB was more beneficial than IONB in achieving the anaesthetic effect of maxillary anterior teeth and premolars. It was a single study included for assessing the postoperative pain using the visual analogue scale and the onset time of anaesthesia for maxillary teeth and was not considered for qualitative synthesis. The onset time of anaesthesia for mandibular teeth was assessed by *Tortamano et al.* (2013) and concluded that 4% articaine exhibited rapid onset with the highest duration of pulpal anaesthesia in IANB. However, since this was a single study, it was not considered for quantitative synthesis (Table 2).

Assessments of the level of evidence, risk of bias, and quality

According to JBI level of evidence, 21 studies (*Gao & Meng*, 2020; *Kumar et al.*, 2020; Aggarwal et al., 2019; Ghazalgoo et al., 2018; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani, 2017; Umesh, 2017; Allegretti et al., 2016; Hosseini et al., 2016; Zain et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Nabeel, Ahmed & Sikander, 2014; Rogers et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b; Aggarwal et al., 2011; Poorni et al., 2011) were ranked at 1c and the remaining 5 studies (Lokhande et al., 2019; Saraf et al., 2016; Ahmad et al., 2014; Tortamano et al., 2013; Subbiya et al., 2011) as 1d.

The quality assessment of 11 RCTs was executed according to the Cochrane Risk of Bias Tool (*Gao & Meng*, 2020; *Kumar et al.*, 2020; *Aggarwal et al.*, 2019; *Ghazalgoo et al.*, 2018; *Lokhande et al.*, 2019; *Martínez-Martínez*, *Freyle-Granados & Senior-Carmona*, 2018; *Shapiro et al.*, 2018; *Aggarwal*, *Singla & Miglani*, 2017; *Umesh*, 2017; *Allegretti et al.*, 2016; *Hosseini et al.*, 2016; *Saraf et al.*, 2016; *Monteiro et al.*, 2015; *Rajput et al.*, 2015; *Nabeel*, *Ahmed & Sikander*, 2014; *Rogers et al.*, 2014; *Sood*, *Hans & Shetty*, 2014; *Ashraf et al.*, 2013; *Tortamano et al.*, 2013; *Kanaa*, *Whitworth & Meechan*, 2012a; *Kanaa*, *Whitworth & Meechan*, 2012b; *Aggarwal et al.*, 2011; *Poorni et al.*, 2011). Moreover, 13 studies (*Gao & Meng*, 2020; *Aggarwal et al.*, 2019; *Martínez-Martínez*, *Freyle-Granados & Senior-Carmona*, 2018; *Shapiro et al.*, 2018; *Aggarwal*, *Singla & Miglani*, 2017; *Umesh*, 2017; *Allegretti et*





Full-size DOI: 10.7717/peerj.12214/fig-2

al., 2016; Hosseini et al., 2016; Monteiro et al., 2015; Rogers et al., 2014; Ashraf et al., 2013; Kanaa, Whitworth & Meechan, 2012a; Aggarwal et al., 2011; Poorni et al., 2011) showed a low potential risk of bias, 3 (Kumar et al., 2020; Monteiro et al., 2015; Sood, Hans & Shetty, 2014) presented a moderate risk and 7 (Lokhande et al., 2019; Saraf et al., 2016; Zain et al., 2016; Rajput et al., 2015; Nabeel, Ahmed & Sikander, 2014; Tortamano et al., 2013; Kanaa, Whitworth & Meechan, 2012b) had a high potential risk of bias (Fig. 2).

MINORS was used for quality assessment of 2 non-randomised comparative studies (*Ahmad et al., 2014; Subbiya et al., 2011*) that presented a score of 21 (Table 3). Only 5/26 studies (*Hosseini et al., 2016; Ahmad et al., 2014; Rogers et al., 2014; Ashraf et al., 2013; Poorni et al., 2011*) disclosed receiving financial support for the work.

Synthesis of results

A total of 22 studies (Gao & Meng, 2020; Kumar et al., 2020; Aggarwal et al., 2019; Lokhande et al., 2019; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani, 2017; Allegretti et al., 2016; Hosseini et al., 2016; Zain et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Ahmad et al., 2014; Nabeel,

Table 3 Methodological index for non-randomized studies (MINORS).

| | A clearly stated aim | Inclusion of con- secutive patients | Prospective col- lection of data | Endpoints appro- priate to the aim of the study | Unbiased assess- ment of the study endpoint | Follow-up period appropriate to the aim of the study | Loss to follow up less than 5% | Prospective calcu- lation of the study size | ^b An adequate control group | ^b Contemporary groups | ^b Baseline equiva- lence of groups | *Adequate statis- tical analyses | Total |
|-----------------------|-------------------------|--|-------------------------------------|---|---|--|-----------------------------------|---|---|-------------------------------------|--|-------------------------------------|-------|
| Ahmad et al. (2014) | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 21 |
| Subbiya et al. (2011) | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 21 |

Notes.

^aThe items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate). The global ideal score being 16 for non-comparative studies and 24 for comparative studies. ^bFor study with control group. Ahmed & Sikander, 2014; Rogers et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Tortamano et al., 2013; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b; Subbiya et al., 2011; Aggarwal et al., 2011; Poorni et al., 2011) fulfilled the inclusion criteria for quantitative analysis. Subsequently, two meta-analyses, including one subgroup analysis, were performed on the success rate of anaesthesia for mandibular and maxillary teeth.

The success rate of anaesthesia for mandibular teeth

The pooled outcomes from 19 studies, in tooth level unit, using random-effect model showed that 4% articaine resulted in a success rate 1.37-fold higher than that of 2% lidocaine (RR, 1.37; 95% CI [1.17–1.62]; P = 0.0002), showing statistically significant difference favouring the articaine group and 72% heterogeneity (I^2) . When subgroup analysis was performed according to the injection techniques using random-effect model, it was observed that for IANB (Kumar et al., 2020; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Aggarwal, Singla & Miglani, 2017; Allegretti et al., 2016; Ahmad et al., 2014; Sood, Hans & Shetty, 2014; Poorni et al., 2011), 4% articaine resulted in a success rate 1.25-fold higher than that for 2% lidocaine (RR, 1.25; 95% CI [0.98–1.59]; P = 0.007) showing statistically significant difference favouring the articaine group with 43% heterogeneity. For BI technique (Kumar et al., 2020; Zain et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Kanaa, Whitworth & Meechan, 2012b; Poorni et al., 2011), 4% articaine resulted in a success rate 1.13-fold higher than that for 2% lidocaine (RR, 1.13; 95% CI [0.89-1.45]; P = 0.31) with 68% heterogeneity. Supplementary BI after IANB failure technique (Gao & Meng, 2020; Shapiro et al., 2018; Rogers et al., 2014; Kanaa, Whitworth & *Meechan*, 2012b) showed that 4% articaine resulted in a success rate of 1.53-fold higher than 2% lidocaine (RR, 1.53; 95% CI [1.821–1.94]; P = 0.0004) showing statistically significant difference favouring the articaine group with the heterogeneity of 36% (I²). BI combined with intraligamentary injection technique (Lokhande et al., 2019) showed that 4% articaine resulted in a success rate of 8.33-fold higher than that for 2% lidocaine (RR, 8.33; 95% CI [2.81-24.67]; P = 0.0001) showing statistically significant difference favouring the articaine group. For supplementary intraligamentary injections after IANB failure (Aggarwal et al., 2019) and standard IANB and long BI technique (Ashraf et al., 2013), 4% articaine resulted in a success rate 0.9-fold (RR, 0.9; 95% CI [0.67–1.2]; P = 0.47) and 2.41-fold (RR, 2.41; 95% CI [1.56–1.2]; P < 0.0001) higher than that of 2% lidocaine, respectively showing statistically significant difference favouring the articaine group for standard IANB and long BI technique but not for supplementary intraligamentary injections after IANB failure. For IANB plus BI technique (Aggarwal et al., 2011), 4% articaine resulted in a success rate of 1.38-fold higher than that for 2% lidocaine (RR, 1.38; 95% CI [0.74–2.6]; P < 0.0001) showing a statistically significant difference favouring the articaine group (Fig. 3).

The success rate of anaesthesia for maxillary teeth

The pooled outcomes from 3 studies (*Hosseini et al., 2016*; *Nabeel, Ahmed & Sikander, 2014*; *Kanaa, Whitworth & Meechan, 2012a*) on tooth level unit for maxillary buccal infiltration technique showed that 4% articaine resulted in a success rate of 1.06-fold higher than that

| | 4% Artic | aine | 2% Lidoo | caine | | Risk Ratio | Risk Ratio |
|--|--|---|---|--|--|---|---------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | M-H, Random, 95% Cl |
| 1.1.1 Inferior alveolar nerv | e block | | | | | | |
| Aggarwal V et al 2017 | 10 | 30 | 7 | 31 | 2.7% | 1.48 [0.65, 3.37] | |
| Ahmad ZH et al 2014 | 13 | 15 | 6 | 15 | 3.6% | 2.17 [1.13, 4.15] | |
| Allergretti CE et al 2016 | 14 | 22 | 12 | 22 | 4.8% | 1.17 [0.71, 1.91] | |
| Kumar BP et al 2020 | 1 | 13 | 2 | 12 | 1.2% | 3.23 [0.83, 12.61] | |
| Martinez AM et al 2018 | 4 | 18 | 1 | 18 | 0.6% | 4.00 [0.49, 32.39] | |
| Poorni Siet al 2011 Rood Dict of 2014 | 30 | 52 | 34 | 52 | 0.8% | 1.06 [0.81, 1.38] | T |
| Sood R et al 2014 Subtotal (95% CI) | 44 | 200 | 41 | 200 | 27 4% | 1.07 [0.91, 1.27] | |
| Total evente | 129 | 200 | 102 | 200 | 21.470 | 120 [0.00, 1.00] | |
| Heterogeneity Tau ² = 0.04 | Chi ² = 1 | 149 df | = 6 (P = 0 | 11) 12= | 43% | | |
| Test for overall effect: Z = 1 | .82 (P = 0 | 0.07) | - 0 (1 - 0 | | 4370 | | |
| 1.1.2 Buccal infiltration | | | | | | | |
| Kumar BP et al 2020 | 5 | 6 | 7 | 10 | 4.4% | 1.19 [0.69, 2.04] | |
| Monteiro MR et al 2015 | 12 | 30 | 2 | 30 | 1.2% | 6.00 [1.47, 24.55] | |
| Poorni S et al 2011 | 34 | 52 | 34 | 52 | 6.7% | 1.00 [0.76, 1.32] | - |
| Rajput F et al 2015 | 22 | 30 | 20 | 30 | 6.2% | 1.10 [0.79, 1.53] | |
| Subbiya A et al 2012 | 22 | 30 | 26 | 30 | 6.9% | 0.85 [0.65, 1.09] | |
| Zain M et al 2016 | 60 | 70 | 49 | 78 | 7.5% | 1.36 [1.12, 1.66] | |
| Subtotal (95% CI) | | 218 | | 230 | 32.9% | 1.13 [0.89, 1.45] | T |
| Total events | 155 | | 138 | | | | |
| Heterogeneity: Tau ² = 0.06 Test for overall effect: Z = 1 | .01 (P = 0) | 5.48, df).31) | = 5 (P = 0 | .009); I* | = 68% | | |
| 1.1.3 Supplementary bucc | al infiltra | tion aft | er IANB fa | ailure | | | |
| Gao X et al 2020 | 43 | 52 | 30 | 52 | 6.9% | 1.43 [1.10, 1.87] | |
| Kanaa D et al 2012 a | 21 | 25 | 8 | 25 | 4.0% | 2.63 [1.45, 4.77] | |
| Rogers BS et al 2014 | 24 | 39 | 13 | 35 | 4.7% | 1.66 [1.01, 2.72] | |
| Shapiro et al 2018 | 47 | 76 | 35 | 73 | 6.6% | 1.29 [0.96, 1.74] | |
| Subtotal (95% CI) | | 192 | | 185 | 22.2% | 1.53 [1.21, 1.94] | • |
| Total events | 135 | 2014-000-04 | 86 | | 2. Section 1. | | |
| Heterogeneity: Tau ² = 0.02 Test for overall effect: Z = 3 | ; Chi ² = 4. .56 (P = 0 | .70, df =).0004) | 3 (P = 0.) | 20); I ^z = 1 | 36% | | |
| 1.1.4 Ruccal infiltration co | mbinod | with intr | aligamor | tanyini | oction | | |
| Lokhande Plet al 2019 | 25 | 30 | angamen 2 | 30 | 1.8% | 8 33 [2 81 - 24 67] | |
| Subtotal (95% Cl) | 20 | 30 | 5 | 30 | 1.8% | 8.33 [2.81, 24.67] | |
| Total events | 25 | | 3 | | non | orea friend, r mont | |
| Heterogeneity: Not applica | hle | | 5 | | | | |
| Test for overall effect: Z = 3 | .83 (P = 0 | 0.0001) | | | | | |
| 115 Supplementary intra | ligament | arv inie | ctions aff | er IANR | failure | | |
| Annanyal V et al 2010 | 27 | 41 | 20 | 41 | 6.6% | 0 0 0 0 7 3 0 0 0 0 | _ |
| Subtotal (95% CI) | 21 | 41 | 50 | 41 | 6.6% | 0.90 [0.67, 1.20] | • |
| Total evente | 27 | | 30 | | 01070 | 0.00[0.01, 1.20] | |
| Heterogeneity: Not annlica | hle | | 50 | | | | |
| Test for overall effect: Z = 0 | ~ ~ ~ | | | | | | |
| | .72 (P = 0 | 1.47) | | | | | |
| 1.1.6 Standard IANB and I | .72 (P = 0 |).47) al inject | ions | | | | |
| 1.1.6 Standard IANB and I Ashraf H et al 2013 | .72 (P = 0 ong bucc 41 |).47) al inject 58 | ions 17 | 58 | 5.3% | 2.41 [1.56. 3.72] | |
| 1.1.6 Standard IANB and I Ashraf H et al 2013 Subtotal (95% CI) | .72 (P = 0 ong bucc 41 | 0.47) al inject 58 58 | ions 17 | 58 58 | 5.3% 5.3 % | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] | Ť |
| 1.1.6 Standard IANB and Id Ashraf H et al 2013 Subtotal (95% CI) Total events | .72 (P = 0 ong bucc 41 41 | 1.47) al inject 58 58 | ions 17 17 | 58 58 | 5.3% 5.3% | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] | — |
| 1.1.6 Standard IANB and Id Ashraf H et al 2013 Subtotal (95% CI) Total events Heterogeneity: Not applica | .72 (P = 0 ong bucc 41 41 ble | 1.47) al inject 58 58 | ions 17 17 | 58 58 | 5.3% 5 . 3% | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] | • |
| 1.1.6 Standard IANB and Id Ashraf H et al 2013 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 3 | .72 (P = 0 ong bucc 41 41 ble .99 (P < 0 | 0.47) al inject 58 58 58 | ions 17 17 | 58 58 | 5.3% 5 .3 % | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] | • |
| 1.1.6 Standard IANB and IA Ashraf H et al 2013 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 3 1.1.7 IANB plus buccal infi | .72 (P = 0 ong bucc 41 41 ble .99 (P < 0 Itration | 0.47) al inject 58 58 0.0001) | ions 17 17 | 58 58 | 5.3% 5 .3 % | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] | * |
| 1.1.6 Standard IANB and IANB and IA Ashraf H et al 2013 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 3 1.1.7 IANB plus buccal infi Aggarwal V et al 2011 | .72 (P = 0 ong bucc 41 41 ble .99 (P < 0 Itration 13 | 0.47) al inject 58 58 0.0001) 24 | ions 17 17 9 | 58 58 23 | 5.3% 5.3 % 3.8% | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] 1.38 [0.74, 2.60] | • |
| 1.1.6 Standard IANB and IA Ashraf H et al 2013 Subtotal (95% Cl) Total events Heterogeneity: Not applica Test for overall effect: Z = 3 1.1.7 IANB plus buccal infi Aggarwal V et al 2011 Subtotal (95% Cl) | .72 (P = 0 ong bucc 41 41 ble .99 (P < 0 Itration 13 | 1.47) al inject 58 58 1.0001) 24 24 24 | ions 17 17 9 | 58 58 23 23 | 5.3% 5.3% 3.8% 3.8% | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] 1.38 [0.74, 2.60] 1.38 [0.74, 2.60] | • |
| 1.1.6 Standard IANB and IA Ashraf H et al 2013 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 3 1.1.7 IANB plus buccal infi Aggarwal V et al 2011 Subtotal (95% CI) Total events | .72 (P = 0 ong bucc 41 41 ble .99 (P < 0 Itration 13 13 | 1.47) al inject 58 58 1.0001) 24 24 24 | ions 17 17 9 9 | 58 58 23 23 | 5.3% 5.3% 3.8% 3.8% | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] 1.38 [0.74, 2.60] 1.38 [0.74, 2.60] | • |
| 1.1.6 Standard IANB and IA Ashraf H et al 2013 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 3 1.1.7 IANB plus buccal infi Aggarwal V et al 2011 Subtotal (95% CI) Total events Heterogeneity: Not applica | .72 (P = 0 ong bucc 41 41 ble .99 (P < 0 Itration 13 13 ble | 1.47) al inject 58 58 1.0001) 24 24 24 | ions 17 17 9 9 | 58 58 23 23 | 5.3% 5.3% 3.8% 3.8% | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] 1.38 [0.74, 2.60] 1.38 [0.74, 2.60] | • |
| 1.1.6 Standard IANB and IA Ashraf H et al 2013 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 3 1.1.7 IANB plus buccal infi Aggarwal V et al 2011 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 1 | .72 (P = 0 ong bucc 41 41 ble .99 (P < 0 Itration 13 13 ble .01 (P = 0 | 1.47) al inject 58 58 1.0001) 24 24 24 | ions 17 17 9 9 | 58 58 23 23 | 5.3% 5.3% 3.8% 3.8% | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] 1.38 [0.74, 2.60] 1.38 [0.74, 2.60] | * |
| 1.1.6 Standard IANB and IA Ashraf H et al 2013 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 3 1.1.7 IANB plus buccal infi Aggarwal V et al 2011 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 1 Total (95% CI) | .72 (P = 0 ong bucc 41 41 99 (P < 0 Itration 13 13 ble .01 (P = 0 | 1.47) al inject 58 58 1.0001) 24 24 1.31) 763 | ions 17 17 9 9 | 58 58 23 23 767 | 5.3% 5.3% 3.8% 3.8% | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] 1.38 [0.74, 2.60] 1.38 [0.74, 2.60] | • |
| 1.1.6 Standard IANB and IA Ashraf H et al 2013 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect. Z = 3 1.1.7 IANB plus buccal infi Aggarwal V et al 2011 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect. Z = 1 Total (95% CI) Total events | .72 (P = 0 ong bucc 41 41 99 (P < 0 Itration 13 13 ble .01 (P = 0 524 | 1.47) al inject 58 58 1.0001) 24 24 24 1.31) 763 | ions 17 17 9 9 9 | 58 58 23 23 767 | 5.3% 5.3% 3.8% 3.8% | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] 1.38 [0.74, 2.60] 1.38 [0.74, 2.60] 1.37 [1.17, 1.62] | • |
| 1.1.6 Standard IANB and IA Ashraf H et al 2013 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 3 1.1.7 IANB plus buccal infi Aggarwal V et al 2011 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 1 Total (95% CI) Total events Heterogeneity: Tau ² = 0.08 | .72 (P = 0 .73 (P = 0 .41 .99 (P < 0 .99 (P < 0 .99 (P < 0 .99 (P = 0 .01 (P = 0 .524 .01 (P = 7 .01 (P = 7 .01 (P = 7) .01 (P = 7) .02 (P = 10 .01 (P = 10) .02 (P = 10) .03 (P = 10) .03 (P = 10) .04 (P = 10) .04 (P = 10) .05 (P = 10) | 1.47) al inject 58 58 1.0001) 24 24 1.31) 763 2.35 df | ions 17 17 9 9 9 386 = 20 (P < | 58 58 23 23 767 0.00001 | 5.3% 5.3% 3.8% 3.8% 100.0% | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] 1.38 [0.74, 2.60] 1.38 [0.74, 2.60] 1.37 [1.17, 1.62] | |
| 1.1.6 Standard IANB and IA Ashraf H et al 2013 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 3 1.1.7 IANB plus buccal infi Aggarwal V et al 2011 Subtotal (95% CI) Total events Heterogeneity: Not applica Test for overall effect: Z = 1 Total events Heterogeneity: Tau ² = 0.08 Test for overall effect: Z = 3 | .72 (P = 0 ong bucc 41 41 ble .99 (P < 0 Itration 13 13 ble .01 (P = 0 524 ; Chi ² = 7; 78 (P = 0 | 1.47) al inject 58 58 1.0001) 24 24 1.31) 763 2.35, df ¹ 1.0002) | ions 17 17 9 9 386 = 20 (P < | 58 58 23 23 767 0.00001 | 5.3% 5.3% 3.8% 3.8% 100.0% | 2.41 [1.56, 3.72] 2.41 [1.56, 3.72] 1.38 [0.74, 2.60] 1.38 [0.74, 2.60] 1.37 [1.17, 1.62] | |

Figure 3 Forest plot of the pooled analysis and the subgroup analysis comparing 4% articaine with 2% lidocaine in the clinical success of mandibular block and infiltration anaesthesia for irreversible pulpitis in tooth unit.

Full-size DOI: 10.7717/peerj.12214/fig-3

| 4% Articaine | | | 2% Lidoc | aine | | Risk Ratio | Risk Ratio |
|--|--------------------------|---------|------------|-------------------------|---|---------------------|---------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | M-H, Random, 95% Cl |
| Hosseini HR et al 2016 | 16 | 24 | 13 | 23 | 6.6% | 1.18 [0.75, 1.86] | |
| Kanaa D et al 2012 b | 33 | 38 | 29 | 35 | 36.1% | 1.05 [0.86, 1.27] | |
| Nabeel M et al 2014 | 35 | 38 | 33 | 38 | 57.3% | 1.06 [0.91, 1.24] | |
| Total (95% CI) | | 100 | | 96 | 100.0% | 1.06 [0.95, 1.20] | • |
| Total events | 84 | | 75 | | | | |
| Heterogeneity: Tau ² = 0.00 | D; Chi ² = 0. | 26, df= | 2 (P = 0.8 | (8); I ² = 1 | 0% | | |
| Test for overall effect: Z = | 1.03 (P = 0 | 1.30) | | | Favours 2% Lidocaine Favours 4% Articaine | | |

Figure 4 Forest plot comparing 4% with 2% lidocaine in the clinical success rate of maxillary buccal infiltration for irreversible pulpitis in tooth unit.

for 2% lidocaine (RR, 1.06; 95% CI [0.95–1.2]; P = 0.3, $I^2 = 0\%$) using random-effects model, showing statistically insignificant difference (Fig. 4).

Sensitivity analysis

Table 4 represents the results of sensitivity analysis for mandibular teeth. Studies of high risk (Lokhande et al., 2019; Saraf et al., 2016; Zain et al., 2016; Rajput et al., 2015; Nabeel, Ahmed & Sikander, 2014; Tortamano et al., 2013; Kanaa, Whitworth & Meechan, 2012b), moderate risk (Kumar et al., 2020; Monteiro et al., 2015; Sood, Hans & Shetty, 2014) or low risk of bias (Gao & Meng, 2020; Kumar et al., 2020; Aggarwal et al., 2019; Ghazalgoo et al., 2018; Lokhande et al., 2019; Martínez-Martínez, Freyle-Granados & Senior-Carmona, 2018; Shapiro et al., 2018; Aggarwal, Singla & Miglani, 2017; Umesh, 2017; Allegretti et al., 2016; Hosseini et al., 2016; Saraf et al., 2016; Monteiro et al., 2015; Rajput et al., 2015; Ahmad et al., 2014; Nabeel, Ahmed & Sikander, 2014; Rogers et al., 2014; Sood, Hans & Shetty, 2014; Ashraf et al., 2013; Tortamano et al., 2013; Kanaa, Whitworth & Meechan, 2012a; Kanaa, Whitworth & Meechan, 2012b; Aggarwal et al., 2011; Poorni et al., 2011) were excluded from sensitivity analysis. The clinical success rates comparing the articaine and lidocaine groups showed a significant change after the exclusion of these studies. Reanalysis using the fixed-effect model also showed that the outcomes were not adverse. The exclusion of subgroups with a single study showed a significant improvement in the success rate of articaine group as compared to the lidocaine group in the treatment of IP. Moreover, the subgroup analysis for different injection techniques showed a significant change after the inclusion of only supplementary BI after IANB failure technique as compared to the inclusion of IANB and BI technique (Table 4).

Publication bias for studies included on mandibular anaesthetic technique was evaluated using a funnel plot (Fig. 5). The funnel plot showed asymmetry at the apex from the centre line having more studies on the right side as compared to left, representing a lack of inclusion of publications describing non-significant intervention results as well as the omission of unpublished studies that might result in an over-estimation of the true effect of an intervention.

DISCUSSION

Endodontic pain management is a critical component in reducing extreme anxiety during endodontic treatment. LA's in-depth and methodical expertise, as well as its suitable delivery

Full-size DOI: 10.7717/peerj.12214/fig-4

| Item | Success of local anaesthesia (RR, 95% CI) |
|--|--|
| Original estimates | 1.37 [1.17, 1.62], P = 0.0002 |
| Exclusion all the studies of high risk of bias | 1.28 [1.09, 1.52], <i>P</i> = 0.003 |
| Exclusion all the studies of moderate risk of bias | 1.41 [1.17, 1.70], <i>P</i> = 0.0003 |
| Exclusion all the studies of low risk of bias | 1.58 [1.12, 2.24], <i>P</i> = 0.003 |
| Inclusion of studies of low risk of bias only | 1.31 [1.08, 1.60], <i>P</i> = 0.003 |
| Fixed or random effects | |
| Fixed effect | 1.37 [1.26, 1.49], P < 0.00001 |
| Random effect | 1.37 [1.17, 1.62], P = 0.0002 |
| Exclusion of subgroups with single study | 1.30 [1.19, 1.41], P = 0.001 |
| Inclusion of IANB only | 1.25 [0.98, 1.59], P = 0.07 |
| Inclusion of buccal infiltration Only | 1.13 [0.89, 1.45], <i>P</i> = 0.31 |
| Inclusion of supplementary buccal infiltration after IANB failure Only | 1.53 [1.21, 1.94], <i>P</i> = 0.0004 |

Table 4Sensitivity and subgroup analysis of the outcomes between articaine and lidocaine group intooth unit for mandibular region.

CI, Confidence interval; IANB, Inferior alveolar nerve block; RR, Relative risk.

methodologies, are essential for pain-free dental treatment (*Aggarwal et al., 2011*). The gold standard amide anaesthetic, lidocaine, has a brief start of action, but when combined with epinephrine, the duration of action increases to intermediate (*Ghazalgoo et al., 2018*). In patients with endodontic discomfort, the success of lidocaine in IANB and infiltration remains low (*Aggarwal et al., 2011*; *Aggarwal, Jain & Debipada, 2009*; *Hargreaves & Keiser, 2002*). The risk of failed local anaesthetic was eight times greater in patients with IP than in normal individuals (*Hargreaves & Keiser, 2002*). Pain is initially transmitted by A-delta and C-fibres in IP, but as the inflammatory process advances, C-fibre transmission takes over, resulting in changed pain characteristics. Strong, quick, acute, and well-localized pain is caused by A-delta fibres, whereas dull, persistent, and radiating pain is caused by C-fibres (*Prpic-Mehicic & Nada, 2010*).

Anatomical causes, acute tachyphylaxis, and the influence of inflammation on local tissue pH, blood flow, nociceptors, central sensitization, and psychological variables are all possible reasons for failure (*Aggarwal et al., 2011; Poorni et al., 2011; Aggarwal, Jain & Debipada, 2009; Reader, Nusstein & Hargreaves, 2011*). Articaine is more effective in reducing the action potential produced by A-fibres as compared to 2% lidocaine and the complete disappearance of the action potential produced by C-fibres (*Allegretti et al., 2016*) (Fig. 6).

This systematic review and meta-analysis of clinical trials provides level 1 evidence for evaluating the efficacy of 4% articaine and 2% lidocaine in the mandibular and maxillary

Notes.



Figure 5 Funnel plot comparing 4% articaine with 2% lidocaine in the clinical success of mandibular block and infiltration anaesthesia for irreversible pulpitis in tooth unit. Full-size DOI: 10.7717/peerj.12214/fig-5

block and infiltration anaesthesia in patients with IP, according to the Oxford Centre for Evidence-Based Medicine's levels of evidence criteria (*Oxford Centre for Evidence-Based Medicine, 2009*). The review included 26 research published between 2011 and 2020 in various countries (24 randomised trials and 2 non-randomised trials). The study participants ranged in age from 15 to 65 years old and were of both genders. Therefore, the findings of this systematic review may be applied to a wide variety of people, as well as anaesthetic effectiveness in mandibular and maxillary teeth with symptomatic IP. Pulp sensitivity tests and the exclusion of periapical diseases were used to determine if research subjects met the criteria for symptomatic IP in the included studies. Participants who have been taking any medication that may affect the impact of local anaesthetic were also excluded from the research, reducing selection bias.

The most common method for anaesthetizing mandibular teeth is IANB (*Zain et al., 2016*). However, IANB is an unreliable anaesthetic method, especially in the case of IP; even when correctly administered, the success rate varied from 15–25% (*Kumar et al., 2020; Shapiro et al., 2018; Zain et al., 2016*). This emphasises the need of having



Figure 6 The chemical structure of lidocaine and articaine. Full-size DOI: 10.7717/peerj.12214/fig-6

alternatives to IANB (*Shapiro et al., 2018*). Thus, in the present systematic review, the pulpal anaesthetic efficacy between articaine and lidocaine were assessed using various infiltration and block techniques. For mandibular teeth IANB, BI, supplementary BI, and intraligamentary injections after IANB failure, BI combined with intraligamentary injection, standard IANB, and long BIs, IANB plus BI and for maxillary teeth *via* BI, AMSA and IONB were used. The 2011 meta-analysis by *Brandt et al. (2011)* found that articaine as an infiltrating agent was 3.8-fold more likely to be successful than lidocaine. A recent meta-analysis by *Kung, McDonagh & Sedgley (2015)* demonstrated that in cases of a failed IANB, supplementary infiltration with 4% articaine was 3.55-fold more successful in achieving profound anaesthetic effect than 2% lidocaine.

Various criteria were applied in this review to assess the first pulpal anaesthetic success, including lip numbness, cold testing, and electric pulp testing. Lip numbness was noted in the majority of the trials, albeit it was a subjective symptom. Only a few studies used a cold test or an electric pulp test followed by lip numbness to validate the first pulpal anaesthetic success, as there was a weak connection between lip anaesthesia, cold testing, and pulpal anaesthesia following IANB for IP mandibular molars (*Shapiro et al., 2018; Umesh, 2017*). Bjorn was the first to link a negative response to the maximal output of electrical pulp stimulation for painless dental treatment (*Bjorn, 1946*). *Dreven et al. (1987*) examined the reaction to an electric pulp tester as a measure of pulpal anaesthetic prior to endodontic treatment in teeth with normal pulp, reversible pulpitis, and irreversible pulpitis. In IP, however, a lack of reaction to cold or electric pulp tests does not always imply pulpal anaesthesia (*Dreven et al., 1987*). This might be because in teeth with IP, the reactions to electric pulp tests and cold testing are linked to rapid and slow silent A-delta fibres, respectively.

Therefore, it can be assumed that if the tetrodotoxin-resistant sodium channels appear on deeper nociceptive C fibres, then neither negative nor positive responses to EPT and cold tests indicate the success of anaesthesia as the C fibres might be accountable for the pain response (*Shapiro et al., 2018*; *Brandt et al., 2011*). Hence, an appropriate alternative is to record the pain response during access cavity opening and pulp extirpation. All the studies included in the systematic review assessed the clinical success of 4% articaine and 2% lidocaine based on pain response during access preparation using VAS.

In this systematic review, the efficacy of anaesthetic solutions was measured by clinical success rate, postoperative discomfort, and local anaesthesia onset time. The meta-analysis of the collected data from 22 studies that satisfied the inclusion criteria was based on the clinical success rate. Furthermore, there was methodological variability in terms of research location, study setting, sample size, number and expertise of investigators performing procedures and diagnosis, volume of LA solution, epinephrine concentration, and marking on the pain scale. This heterogeneity was addressed by using a random-effects model for meta-analysis (Kung, McDonagh & Sedgley, 2015). This meta-analysis found that when used in mandibular and maxillary block and infiltration anaesthesia, 4% articaine, which is a more concentrated LA solution, was more likely to provide anaesthetic success than less concentrated 2% lidocaine anaesthetic solution. Besides, wide CIs were observed in the forest plot analysis, potentially contributing to heterogeneity as shown by I² estimates, *i.e.*, 72%, with statistically significant difference favouring the articaine group for mandibular teeth (Fig. 3) as compared to narrower CIs contributing to 0% heterogeneity favouring the articiane group with non-significant difference favouring the articaine group for maxillary teeth (Fig. 4). Similar results were reported by previous meta-analysis that were conducted (Su et al., 2016; De Geus et al., 2020; Kung, McDonagh & Sedgley, 2015; Brandt et al., 2011). Discrepancies in the chemical properties of the molecular structures of the 4 percent articaine and 2 percent lidocaine LA agents might have resulted in clinical differences. The uncharged form of a LA molecule is required for diffusion across the sheaths of lipid neurons and cell membranes, therefore the anaesthetic dissociation constant (pKa) is a crucial number for successful anaesthesia (*De Geus et al.*, 2020). In addition to ionisation, fat solubility and protein-binding properties contribute to the clinical characteristics of LAs whereas, their clinical performance is influenced by the site of injection, concentration of drug and vasoconstrictor, injection volume, and anaesthetic solution's inherent vasodilatory properties (De Geus et al., 2020; Haas, 2002; Moore & Hersh, 2010). A previous study showed that articaine suppresses the compound action potential of the A fibres in the isolated rat sural nerve (*Potonik et al., 2006*). Also, ionic channels are blocked even in lower concentrations with the thiophene derivative (articaine) as compared to the benzene derivative (lidocaine) (Kolli, Nirmala & Nuvvula, 2017).

The differences in the method of delivery of LA for mandibular teeth for the included trials were one of the major challenges posed by this meta-analysis. In the sub-group analysis, a significant advantage of using articaine over lidocaine for supplementary infiltration after mandibular block anaesthesia over the mandibular block and infiltration anaesthesia alone was observed with heterogeneity of 36% (Fig. 3). Another meta-analysis by *Brandt et al. (2011)* showed that the pulpal anaesthetic efficacy of articaine was markedly superior to lidocaine when used during infiltration. One study each for supplementary

intraligamentary injection, IANB plus long buccal, and IANB with BI was included in the subgroup analysis for mandibular teeth. However, to evaluate whether the final results were dependent on subgroup results of these single studies, a sensitivity analysis was performed *via* meta-analysis by excluding the above studies in question. This analysis confirmed that although the exclusion of the studies reduced the RRs and heterogeneity, the overall results were unchanged (Table 4).

The secondary objective of this systematic review was to assess the postoperative pain and mean onset time of the two LA solutions. The group receiving 4% articaine, as opposed to 2% lidocaine, experienced less pain as measured by VAS during the injection and treatment phases, which might be due to articaine's 1.5-fold higher potency than lidocaine's (*Su et al., 2016*). In terms of onset time, 4 percent articaine was shown to be faster than 2 percent lidocaine in pulpal anaesthesia. This phenomenon might be explained by the fact that the onset period of anaesthesia is proportional to the pace of epineural diffusion. This rate is proportional to the percentage of drug in the base form, which is proportional to the pKa; articaine's pKa was lower than lidocaine's (*Su et al., 2016*).

Intriguingly, when this study was compared to prior English language systematic reviews (*Su et al., 2016; Kung, McDonagh & Sedgley, 2015; Brandt et al., 2011; Katyal, 2010*), there were some striking similarities and variations in terms of anaesthetic solution and administration techniques. Except for the reviews by *Su et al. (2016)* and Kung et al. (*Brandt et al. 2011*), the main difference between this and previous reviews (*Su et al., 2016; Kung, McDonagh & Sedgley, 2015; Brandt et al., 2011; Katyal, 2010*) is that all subjects in this review were diagnosed with IP, whereas previous reviews consisted of a broad cohort of patients and non-patient volunteers with or without pain (*Srinivasan et al., 2017; Kung, McDonagh & Sedgley, 2015*). In comparison to the current analysis, which comprised parallel-design clinical trials, earlier reviews by *Brandt et al. (2011)* and *Katyal (2010)* used crossover design. In comparison to prior research, the start and end of the search time changed in the current study. Previous studies mostly looked at adverse events, pain, and the onset of local anaesthetic, but this study examined at the total clinical success rate as well as subgroup and sensitivity analyses.

Nevertheless, the present review has some limitations. It was not possible to fully avoid the clinical heterogeneity among the included studies. The sample size of the studies was small, thus lacking statistical power. The reasons for the difference in postoperative pain and the onset time could not be explained because of lack of evidence. Individual tooth type analysis (incisors, canines, premolars, and molars) was not performed, and age and gender were also not taken into consideration in the analysis. However, 15 studies rated good on methodological validity assessment, exhibiting a low risk of bias. The subgroup and sensitivity analyses were performed to rule out the potential reasons for heterogeneity. Thus, it is suggested that in the future, high-quality clinical trials on the outcomes of onset of anaesthesia and pain assessment at various stages of the treatment procedure of IP should be conducted along with the trials assessing the adverse effects of the two solutions at varying concentrations and sites of injection.

CONCLUSIONS

The current systematic review and meta-analysis found that whether administered for mandibular block or maxillary infiltration in patients with symptomatic IP, articaine is superior to lidocaine. For mandibular teeth, 4 percent articaine had a clinical success rate 1.37 times greater than 2 percent lidocaine, and 1.06 times higher for maxillary teeth.

KEY HIGHLIGHTS of the current analysis

- 1. Successful pulpal anaesthesia is the cornerstone for painless root canal treatment, especially in patients with symptomatic pulpitis.
- 2. Articaine was introduced to overcome supplemental anaesthesia and to increase the effectiveness of the quality of anaesthesia.
- 3. Articaine is associated with a lower visual analogue scale rating for pain.
- 4. Articaine resulted in 1.37-fold and 1.06-fold higher clinical success rate than lidocaine for mandibular and maxillary teeth respectively.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The authors received no funding for this work.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Sanjay Miglani conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
- Irfan Ansari conceived and designed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
- Swadheena Patro and Ankita Mohanty performed the experiments, prepared figures and/or tables, and approved the final draft.
- Shahnaz Mansoori and Bhoomika Ahuja performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
- Mohmed Isaqali Karobari conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Krishna Prasad Shetty, Musab Hamed Saeed and Alexander Maniangat Luke analyzed the data, authored or reviewed drafts of the paper, and approved the final draft.
- Ajinkya M. Pawar conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the paper, and approved the final draft.

Data Availability

The following information was supplied regarding data availability: This is a review article. There is no raw data.

Supplemental Information

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/ peerj.12214#supplemental-information.

REFERENCES

- Aggarwal V, Jain A, Debipada K. 2009. Anesthetic efficacy of supplemental buccal and lingual infiltrations of articaine and lidocaine following an inferior alveolar nerve block in patients with irreversible pulpitis. *Journal of Endodontics* 35:925–929 DOI 10.1016/j.joen.2009.04.012.
- **Aggarwal V, Singla M, Miglani S. 2017.** Comparative evaluation of anesthetic efficacy of 2% lidocaine, 4% articaine, and 0.5% bupivacaine on inferior alveolar nerve block in patients with symptomatic irreversible pulpitis: a prospective, randomized, double-blind clinical trial. *Journal of Orofacial Pain* **31**(2):124–128.
- Aggarwal V, Singla M, Miglani S, Kohli S. 2019. Efficacy of articaine versus lidocaine administered as supplementary intraligamentary injection after a failed inferior alveolar nerve block: a randomised double-blind study. *Journal of Endodontics* 45(1):1–5.
- **Aggarwal V, Singla M, Rizvi A, Miglani S. 2011.** Comparative evaluation of local infiltration of articaine, articaine plus ketorolac, and dexamethasone on anesthetic efficacy of inferior alveolar nerve block with lidocaine in patients with irreversible pulpitis. *Journal of Endodontics* **37**(4):445–449 DOI 10.1016/j.joen.2011.01.016.
- Ahmad ZH, Ravikumar H, Karale R, Preethanath RS, Sukumaran A. 2014. Study of the anesthetic efficacy of inferior alveolar nerve block using articaine in irreversible pulpitis. *Journal of Contemporary Dental Practice* 15(1):71–74 DOI 10.5005/jp-journals-10024-1490.
- Allegretti CE, Sampaio RM, Horliana AC, Armonia PL, Rocha RG, Tortamano IP. 2016. Anesthetic efficacy in irreversible pulpitis: a randomised clinical trial. *Brazilian Dental Journal* 27(4):381–386 DOI 10.1590/0103-6440201600663.
- Ashraf H, Kazem M, Dianat O, Noghrehkar F. 2013. Efficacy of articaine versus lidocaine in block and infiltration anesthesia administered in teeth with irreversible pulpitis: a prospective, randomised, double-blind study. *Journal of Endodontics* 39(1):6–10 DOI 10.1016/j.joen.2012.10.012.
- **Bjorn H. 1946.** Electrical excitation of teeth and its application to dentistry. *Swedish Dental Journal* **39**:87–96.
- Brandt RG, Anderson PF, McDonald NJ, Sohn W, Peters MC. 2011. The pulpal anesthetic efficacy of articaine versus lidocaine in dentistry: a meta-analysis. *The Journal of the American Dental Association* 142(5):493–504 DOI 10.14219/jada.archive.2011.0219.
- **De Geus JL, Da Costa JK, Wambier LM, Maran BM, Loguercio AD, Reis A. 2020.** Different anesthetics on the efficacy of inferior alveolar nerve block in patients with irreversible pulpitis: a network systematic review and meta-analysis. *The Journal of the American Dental Association* **151**(2):87–97 DOI 10.1016/j.adaj.2019.09.002.

- **Dou L, Luo J, Yang D, Wang Y. 2013.** The effectiveness of an additional lingual infiltration in the pulpal anesthesia of mandibular teeth: a systematic review. *Quintessence International* **44**:457–464.
- Dou L, Vanschaayk MM, Zhang Y, Fu X, Ji P, Yang D. 2018. The prevalence of dental anxiety and its association with pain and other variables among adult patients with irreversible pulpitis. *BMC Oral Health* 18(1):101 DOI 10.1186/s12903-018-0563-x.
- Dreven LJ, Reader A, Beck M, Meyers WJ, Weaver J. 1987. An evaluation of an electric pulp tester as a measure of analgesia in human vital teeth. *Journal of Endodontics* 13:233–238 DOI 10.1016/S0099-2399(87)80097-3.
- Gao X, Meng K. 2020. Comparison of articaine, lidocaine and mepivacaine for buccal infiltration after inferior alveolar nerve block in mandibular posterior teeth with irreversible pulpitis. *British Dental Journal* 228(8):605–608 DOI 10.1038/s41415-020-1434-9.
- **Ghazalgoo A, Saatchi M, Khazaei S, Shadmehr E. 2018.** The effect of using articaine versus lidocaine for inferior alveolar nerve block on pain after root canal treatment: a prospective, randomised clinical study. *Dent Hypotheses* **9(4)**:80 DOI 10.4103/denthyp.denthyp_70_18.
- Haas DA. 2002. An update on local anesthetics in dentistry. *Journal of Canadian Dental Association* 68(9):546–551.
- Hargreaves KM, Keiser K. 2002. Local anesthetic failure in endodontics: mechanisms and management. *Endodontic Topics* 1:26–39 DOI 10.1034/j.1601-1546.2002.10103.x.
- Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds.) 2019. *Cochrane handbook for systematic reviews of interventions*. Hoboken: John Wiley & Sons, 23.
- Hosseini HR, Parirokh M, Nakhaee N, Abbott PV, Samani S. 2016. Efficacy of articaine and lidocaine for buccal infiltration of first maxillary molars with symptomatic irreversible pulpitis: a randomised double-blinded clinical trial. *IEJ* 11(2):79.
- **Howait M, Basunbul GI. 2019.** Prevalence of failed inferior alveolar nerve block (IANB) in achieving pulpal anaesthesia in mandibular molars with symptomatic irreversible pulpitis. *E.D.J* **65**:771–776.
- Kanaa MD, Whitworth JM, Meechan JG. 2012a. A comparison of the efficacy of 4% articaine with 1: 100,000 epinephrine and 2% lidocaine with 1: 80,000 epinephrine in achieving pulpal anesthesia in maxillary teeth with irreversible pulpitis. *Journal of Endodontics* 38(3):279–282 DOI 10.1016/j.joen.2011.11.010.
- Kanaa MD, Whitworth JM, Meechan JG. 2012b. A prospective randomised trial of different supplementary local anesthetic techniques after failure of inferior alveolar nerve block in patients with irreversible pulpitis in mandibular teeth. *Journal of Endodontics* 38(4):421–425 DOI 10.1016/j.joen.2011.12.006.
- **Katyal V. 2010.** The efficacy and safety of articaine versus lignocaine in dental treatments: a meta-analysis. *Journal of Dentistry* **38**(**4**):307–317 DOI 10.1016/j.jdent.2009.12.003.
- **Kolli NK, Nirmala SV, Nuvvula S. 2017.** The effectiveness of articaine and lidocaine single buccal infiltration versus conventional buccal and palatal injection using

lidocaine during primary maxillary molar extraction: a randomised control trial. *Anesthesia, Essays and Researches* **11(1)**:160 DOI 10.4103/0259-1162.186589.

- Kumar BP, Sirisha K, Jyothi M, Rao SA. 2020. Comparative evaluation of anesthetic efficacy of 2% lidocaine and 4% articaine in irreversible pulpitis cases during endodontic therapy –a randomised double blind study. *Indian Journal of Conservative* and Endodontics 5(1):6–10.
- Kung J, McDonagh M, Sedgley CM. 2015. Does articaine provide an advantage over lidocaine in patients with symptomatic irreversible pulpitis? A systematic review and meta-analysis. *Journal of Endodontics* 41(11):1784–1794 DOI 10.1016/j.joen.2015.07.001.
- Li C, Yang X, Ma X, Li L, Shi Z. 2012. Preoperative oral nonsteroidal anti-inflammatory drugs for the success of the inferior alveolar nerve block in irreversible pulpitis treatment: a systematic review and meta-analysis based on randomised controlled trials. *Quintessence International* **43**:209–219.
- Lokhande P, Shivanna V, Manne D, Vidhi S. 2019. Efficacy of articaine versus lidocaine, as a buccal infiltration combined with intraligamentary injection, in mandibular molars with irreversible pulpitis–a clinical trial study. *Journal of Evolution of Medical and Dental Sciences* 8(15):1216–1219 DOI 10.14260/jemds/2019/269.
- Martínez-Martínez A, Freyle-Granados E, Senior-Carmona N. 2018. Efficacy of 2% lidocaine and 4% articaine in mandibular molars with different pulp diagnoses in the mandibular technique. *Revista Facultad de Odontología Universidad de Antioquia* **30(1)**:5–13.
- Modaresi J, Davoudi A, Badrian H, Sabzian R. 2016. Irreversible pulpitis and achieving profound anesthesia: complexities and managements. *Anesthesia, Essays and Researches* **10**(1):3 DOI 10.4103/0259-1162.164675.
- Monteiro MR, Groppo FC, Haiter-Neto F, Volpato MC, Almeida JF. 2015. 4% articaine buccal infiltration versus 2% lidocaine inferior alveolar nerve block for emergency root canal treatment in mandibular molars with irreversible pulpits: a randomised clinical study. *International Endodontic Journal* **48(2)**:145–152 DOI 10.1111/iej.12293.
- Moore PA, Hersh EV. 2010. Local anesthetics: pharmacology and toxicity. *Dental Clinics* of North America 54:587–599 DOI 10.1016/j.cden.2010.06.015.
- Nabeel M, Ahmed A, Sikander M. 2014. A comparison of the anesthetic efficacy oflidocaine and articaine for buccal infiltration in patients with acute irreversiblepulpitis in maxillary first premolars. Pakistan Oral & Dental Journal 34(4):714–716.
- Oxford Centre for Evidence-Based Medicine. 2009. Levels of evidence. *BJU International* 104(2):286 DOI 10.1111/j.1464-410X.2009.08754.x.
- Poorni S, Veniashok B, Senthilkumar AD, Indira R, Ramachandran S. 2011. Anesthetic efficacy of four percent articaine for pulpal anesthesia by using inferior alveolar nerve block and buccal infiltration techniques in patients with irreversible pulpitis: a prospective randomised double-blind clinical trial. *Journal of Endodontics* 37(12):1603–1607 DOI 10.1016/j.joen.2011.09.009.

- Potonik I, Tomi M, Sketelj J, Bajrovi FF. 2006. Articaine is more effective than lidocaine or mepivacaine in rat sensory nerve conduction block in vitro. *Journal of Dental Research* 85:162–166 DOI 10.1177/154405910608500209.
- Prpic-Mehicic G, Nada G. 2010. Odontogenic pain. Medical Sciences 34:43-54.
- **Rajput F, Katpar S, Shaikh MI, Khatoon S. 2015.** Evaluation of anesthetic efficacy of 4% articaine as buccal infiltration vs 2% lidocaine as ianb in the mandibular 1st molar with irreversible pulpitis. *Pakistan Oral & Dental Journal* **35**(1):125–373.
- **Reader A, Nusstein JM, Hargreaves KM. 2011.** Local anesthesia in endodontics. In: Hargreaves KM, Cohen S, eds. *Cohen's Pathways of the Pulp*. St. Louis: Mosby, 691–719.
- Rôças IN, Lima KC, Assunção IV, Gomes PN, Bracks IV, SiqueiraJr JF. 2015. Advanced caries microbiota in teeth with irreversible pulpitis. *Journal of Endodontics* 41(9):1450–1455 DOI 10.1016/j.joen.2015.05.013.
- **Rogers BS, Botero TM, McDonald NJ, Gardner RJ, Peters MC. 2014.** Efficacy of articaine versus lidocaine as a supplemental buccal infiltration in mandibular molars with irreversible pulpitis: a prospective, randomised, double-blind study. *Journal of Endodontics* **40(6)**:753–758 DOI 10.1016/j.joen.2013.12.022.
- Saraf SP, Saraf PA, Kamatagi L, Hugar S, Tamgond S, Patil J. 2016. A comparative evaluation of anesthetic efficacy of articaine 4% and lidocaine 2% with anterior middle superior alveolar nerve block and infraorbital nerve block: an in vivo study. *Journal of Conservative Dentistry* **19(6)**:527 DOI 10.4103/0972-0707.194021.
- Shahi S, Rahimi S, Yavari HR, Ghasemi N, Ahmadi F. 2018. Success rate of 3 injection methods with articaine for mandibular first molars with symptomatic irreversible pulpitis: a CONSORT randomised double-blind clinical trial. *Journal of Endodontics* 44(10):1462–1466 DOI 10.1016/j.joen.2018.07.010.
- Shapiro MR, McDonald NJ, Gardner RJ, Peters MC, Botero TM. 2018. Efficacy of articaine versus lidocaine in supplemental infiltration for mandibular first versus second molars with irreversible pulpitis: a prospective, randomised, double-blind clinical trial. *Journal of Endodontics* 44(4):523–528 DOI 10.1016/j.joen.2017.10.003.
- **Sherman MG, Flax M, Namerow K, Murray PE. 2008.** Anesthetic efficacy of the Gow-Gates injection and maxillary infiltration with articaine and lidocaine for irreversible pulpitis. *Journal of Endodontics* **34(6)**:656–659 DOI 10.1016/j.joen.2008.02.016.
- Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. 2003. Methodological index for non-randomised studies (MINORS): development and validation of a new instrument. ANZ Journal of Surgery 73(9):712–716 DOI 10.1046/j.1445-2197.2003.02748.x.
- Sood R, Hans MK, Shetty S. 2014. Comparison of anesthetic efficacy of 4% articaine with 1: 100,000 epinephrine and 2% lidocaine with 1: 80,000 epinephrine for inferior alveolar nerve block in patients with irreversible pulpitis. *Journal of Clinical and Experimental Dentistry* 6(5):e520.
- Srinivasan MR, Poorni S, Nitharshika Y, Diana D, Duraivel D. 2017. Articaine buccal infiltration versus lignocaine inferior alveolar block for pulpal anaesthesia in mandibular second premolars–Randomised control double blinded

clinical trial. *Journal of Pierre Fauchard Academy (India Section)* **31(2-4)**:79–83 DOI 10.1016/j.jpfa.2017.03.005.

- Su N, Li C, Wang H, Shen J, Liu W, Kou L. 2016. Efficacy and safety of articaine versus lidocaine for irreversible pulpitis treatment: a systematic review and metaanalysis of randomised controlled trials. *Australian Endodontic Journal* 42(1):4–15 DOI 10.1111/aej.12125.
- Subbiya A, Pradeepkumar AR. 2016. Pain management in endodontics. *Journal of Operative Dentistry & Endodontics* 1(2):76–81.
- Subbiya A, Pradeepkumar AR, Vivekanandhan P, Karthick A. 2011. Comparative efficacy evaluation of articaine as buccal infiltration and lignocaine as IANB in the mandibular first molar with irreversible pulpitis. *Indian Journal of Multidisciplinary Dentistry* 2(1):370–373.
- The Joanna Briggs Institute. 2014. Supporting document for the joanna briggs institute levels of evidence and grades of recommendation. Adelaide: The Joanna Briggs Institute. Available at https://jbi.global/sites/default/files/2019-05/JBI%20Levels% 20of%20Evidence%20Supporting%20Documents-v2.pdf (accessed on 23 October 2020).
- Tortamano IP, Siviero M, Lee S, Sampaio RM, Simone JL, Rocha RG. 2013. Onset and duration period of pulpal anesthesia of articaine and lidocaine in inferior alveolar nerve block. *Brazilian Dental Journal* 24(4):371–374 DOI 10.1590/0103-6440201302072.
- Umesh G. 2017. Comparative evaluation of anaesthetic efficacy of 2% lidocaine+ 1: 80,000 epinephrine and 4% articaine+ 1: 1,00,000 epinephrine buffered with 0.5 Mol/L mannitol Or 8.4% sodium bicarbonate on the success of inferior alveolar nerve block for teeth with symptomatic irreversible pulpitis: an invivo study. Doctoral dissertation, Tamil Nadu Government Dental College and Hospital, Chennai.
- World Health Organization. 2017. Sugars dental caries World Health Organization. *Available at https://apps.who.int/iris/bitstream/handle/10665/259413/WHO-NMH-NHD-17.12-eng.pdf* (accessed on 23 October 2020).
- Zain M, Rehman SK, Sikandar H, Shah SA. 2016. Comparison of anaesthetic efficacy of 4% articaine primary buccal infiltration versus 2% lidocaine inferior alveolar nerve block in symptomatic mandibular first molar teeth. *JCPSP* 26(1):4–8.
- Zanjir M, Lighvan NL, Yarascavitch C, Beyene J, Shah PS, Azarpazhooh A. 2019.
 Efficacy and safety of pulpal anaesthesia strategies during endodontic treatment of permanent mandibular molars with symptomatic irreversible pulpitis: a systematic review and network meta-analysis. *Journal of Endodontics* 45(12):1435–1464
 DOI 10.1016/j.joen.2019.09.002.